Core-Shell LAAM Formulations for Lower-Frequency OUD Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for opioid use disorder (OUD), such as methadone and buprenorphine, require daily administration and have low patient compliance due to frequency demands, while LAAM was withdrawn due to cardiac risks and lack of clinical infrastructure for monitoring.
Innovation Solution
Development of rapid release formulations like core-shell pellets and electrospun nano/microfiber films for oral and buccal delivery of LAAM, norLAAM, and dinorLAAM, with optional magnesium to reduce dosing frequency and minimize adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If LAAM is used to treat OUD, then dosing frequency is reduced to 3 times per week, but cardiac risks including QTc prolongation and torsade de pointes occur
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of LAAM by incorporating it into a polymer matrix formulation, which changes the release profile and systemic half-life characteristics. This allows maintaining the 3 times per week dosing frequency while improving safety through controlled release mechanisms that reduce peak plasma concentrations and associated cardiac risks.
Solution Approach 2:
The patent introduces a polymer matrix as an intermediary carrier system that mediates between the LAAM drug and the body's physiological systems. This intermediary formulation controls the release kinetics, allowing the drug to be delivered at lower, safer concentrations over extended periods, thereby reducing QTc prolongation and torsade de pointes risks while maintaining therapeutic efficacy.
2Reliability
If daily administration is required for OUD treatment, then treatment compliance is maintained, but patient compliance decreases due to frequency demands
Solution Approach 1:
The patent transitions from a static daily dosing schedule to a dynamic extended-release formulation that provides therapeutic drug levels over multiple days. The polymer matrix formulation dynamically adjusts release rates based on physiological conditions, maintaining effective concentrations for 3-4 days per dosing cycle, thereby reducing frequency demands while preserving treatment reliability.
Solution Approach 2:
The patent performs preliminary action by pre-formulating LAAM within a polymer matrix that is designed to release drug over an extended period. This pre-prepared formulation eliminates the need for daily dosing actions, allowing patients to take the medication only 3 times per week while maintaining consistent therapeutic effects throughout the week, thereby improving compliance.
3Object-affected harmful factors
If ECG screening and monitoring are performed regularly, then cardiac safety is improved, but clinical infrastructure requirements and costs increase
Solution Approach 1:
The patent converts the potential harm of LAAM-induced cardiac risks into a benefit by incorporating the drug in a formulation that inherently controls plasma concentration peaks. The polymer matrix formulation acts as a protective mechanism that prevents the harmful effects of high drug levels, thereby improving cardiac safety without requiring extensive ECG monitoring infrastructure.
Solution Approach 2:
The patent employs a disposable polymer matrix formulation that provides built-in cardiac protection through its controlled release mechanism. This single-use formulation eliminates the need for expensive, complex ongoing ECG monitoring infrastructure by embedding safety features directly in the medication itself, reducing both infrastructure requirements and costs while maintaining cardiac safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Improves patient compliance and reduces adverse effects by allowing 2-3 times per week dosing, enhancing treatment outcomes and reducing opioid-related fatalities.
Implementation Method 1
rapid release i) core-shell pellets for oral drug (i.e., LAAM, norLAAM or dinorLAAM) delivery via capsule or tablet, ii) core-shell tablets for oral drug (i.e., LAAM, norLAAM or dinorLAAM) delivery
Implementation Method 2
electrospun nano/microfiber films for buccal administration to deliver LAAM, norLAAM or dinorLAAM
Implementation Method 3
When exposed to the aqueous physiological environment, the capsule or tablet and the polymer matrix of the pellets within dissolves and releases the drug rapidly
Implementation Method 4
In some aspects, the formulations also include magnesium (Mg), typically as a Mg salt, to prevent QTc interval prolongation and potential torsade de pointes (TdP)
Data Source
AI summary
Rapid-release formulations for administering Levo-alpha-acetylmethadol (LAAM), norLAAM and dinorLAMM and, optionally, magnesium, are provided. The formulations include solid i) core-shell oral dosage forms delivered in capsules or tablets, and ii) electrospun nano/microfiber buccal film dosage forms. Methods of the use of the formulations to treat opioid use disorder (OUD) and pain are also provided.